Headquartered in The Mediaworks, London Fiscal year ends December NASDAQ: AUTL autolus.com
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company that develops, manufactures, and delivers next-generation programmed T cell therapies for cancer and autoimmune disease. The company uses proprietary and modular T cell programming technologies to engineer precisely targeted CAR T cell therapies. Its marketed product, AUCATZYL (obecabtagene autoleucel; obe-cel), is a CD19-directed CAR T cell therapy approved by the FDA for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), with conditional marketing authorization in the UK and EU. The company has a pipeline of clinical programs exploring obe-cel in lupus nephritis, pediatric ALL, progressive multiple sclerosis, and systemic lupus erythematosus, as well as AUTO8 in light-chain amyloidosis. Autolus trades on Nasdaq under the ticker AUTL and operates manufacturing and commercial capabilities across the US and UK, with 82 U.S. authorized treatment centers for AUCATZYL delivery. Updated
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Monday’s top analyst upgrades and downgrades included Chipotle Mexican Grill, CRISPR, Hess Midstream, iMedia Brands, Kinder Morgan, Wendy’s and more.
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company that develops, manufactures, and delivers next-generation programmed T cell therapies for cancer and autoimmune disease. The company uses proprietary and modular T cell programming technologies to engineer precisely targeted CAR T cell therapies.
The Wall Street consensus 12-month price target for AUTL is $8.72.
